Venor Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Venor Pharma Limited Pharmaceutical Export Portfolio Dataset — 9 Products, $8.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Venor Pharma Limited — Pharmaceutical Exporter Profile (2026) | 9 Products, $8.6M Trade | TransData Nexus

Venor Pharma Limited

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $8.6M Total Trade · DGFT Verified

Venor Pharma Limited is an Indian pharmaceutical exporter with a total trade value of $8.6M across 9 products in 4 therapeutic categories. Based on 497 verified export shipments from Indian Customs (DGFT) records, Venor Pharma Limited is the #1 Indian exporter in 1 product including Diazepam. Top exports include Morphine ($4.4M), Diazepam ($1.4M), Fentanyl ($1.2M).

Venor Pharma Limited — Export Portfolio & Destination Treemap

Venor Pharma Limited pharmaceutical export portfolio — 9 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Venor Pharma Limited? — Company Overview & Market Position

Venor Pharma Limited is a public limited company incorporated on May 3, 2013, in Delhi, India, with Corporate Identification Number (CIN) U74900DL2013PLC251565. The company is registered under the Registrar of Companies (RoC) Delhi. Its authorized capital is ₹5.00 crore, with a paid-up capital of ₹1.00 million. The registered office is located at A-43, Ground Floor, G.T. Karnal Road Industrial Area, Delhi, 110033.

Venor Pharma Limited specializes in the manufacturing and export of pharmaceutical finished formulations, focusing on controlled drug items, including narcotics and psychotropic substances. The company has established a significant presence in the global pharmaceutical market, exporting products across various therapeutic categories. As of March 2026, Venor Pharma Limited has a workforce of 170 employees.

What Does Venor Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Morphine$4.4M 2Diazepam

Product Portfolio — Top 9 by Export Value

Venor Pharma Limited exports 9 pharmaceutical products across 4 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Morphine	Analgesics & Antipyretics	$4.4M	182	24.5%	2
2	Diazepam	CNS & Psychiatric	$1.4M	98	18.4%	1
3	Fentanyl	Analgesics & Antipyretics	$1.2M	76	32.7%	2
4	Codeine	Analgesics & Antipyretics	$740.8K	36	0.7%	7
5	Ephedrine	Respiratory & OTC	$395.9K	58	1.8%	10
6	Amiodarone	Cardiovascular	$179.1K	23	0.2%	15
7	Lorazepam	CNS & Psychiatric	$150.0K	3	6.0%	3
8	Digoxin	Cardiovascular	$67.5K	7	3.1%	5
9	Clonazepam	CNS & Psychiatric	$53.1K	14	0.0%	11

Venor Pharma Limited exports 9 pharmaceutical products across 4 therapeutic categories with a total export value of $8.6M. The company is the #1 Indian exporter in 1 product: Diazepam. The top category is Analgesics & Antipyretics (74.0% of portfolio), followed by CNS & Psychiatric (18.5%), indicating a concentrated portfolio with the top 5 products accounting for 94.7% of total export value.

Venor Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Venor Pharma Limited operates a state-of-the-art manufacturing facility located in Dehradun, Uttarakhand. This facility specializes in the production of pharmaceutical finished formulations, including controlled drug medicines such as narcotics and psychotropic products. The plant is equipped with advanced technology to manufacture a diverse range of dosage forms, including sterile injectables, transdermal drug delivery systems, oral dissolving films, and oral solid dosage forms. The facility adheres to international standards and holds approvals from various regulatory bodies, ensuring compliance and quality in its manufacturing processes.

3Key Leadership

The leadership team at Venor Pharma Limited comprises several key individuals:

Shubham Verma: Director, appointed on August 31, 2018.
Yogesh Kapoor: Director, appointed on February 8, 2023.
Shivam Verma: Director, appointed on May 24, 2023.
Vishwas Verma: Director, appointed on May 3, 2013.
Ritesh Khetarpal: Director, appointed on June 1, 2024.
Savita Verma: Director, appointed on May 3, 2013.

These directors collectively oversee the strategic direction and operations of Venor Pharma Limited, contributing to its growth and success in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Venor Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Venor Pharma Limited has established a strong presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Dehradun, Uttarakhand, has been inspected and approved by various international regulatory bodies, such as the Saudi Food and Drug Authority (SFDA), Ministry of Health (MOH) UAE, Food and Drug Administration (FDA) Iraq, Sudanese National Medicines and Poisons Board (NMPB), Ethiopian Food, Medicine and Health Care Administration and Control Authority (FMHACA), Medicines Control Authority of Zimbabwe (MCAZ), Zambia Medicines Regulatory Authority (ZAMRA), Ghana Food and Drugs Authority (FDA), Tanzania Medicines and Medical Devices Authority (TMDA), Pharmacy and Poisons Board (PPB) Kenya, National Drug Authority (NDA) Uganda, and Pharmacy, Medicines and Poisons Board (PMPB) Malawi. These approvals facilitate the company's market access and distribution in these regions.

2Emerging Markets

Venor Pharma Limited has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's manufacturing facility holds approvals from the World Health Organization's Good Manufacturing Practice (WHO-GMP) certification, which is essential for accessing and distributing pharmaceutical products in these regions. Additionally, the facility has received approvals from various national regulatory authorities, including the Ethiopian Food, Medicine and Health Care Administration and Control Authority (FMHACA), Medicines Control Authority of Zimbabwe (MCAZ), Zambia Medicines Regulatory Authority (ZAMRA), Ghana Food and Drugs Authority (FDA), Tanzania Medicines and Medical Devices Authority (TMDA), Pharmacy and Poisons Board (PPB) Kenya, National Drug Authority (NDA) Uganda, and Pharmacy, Medicines and Poisons Board (PMPB) Malawi. These certifications and approvals enable Venor Pharma Limited to effectively penetrate and operate in these emerging markets.

Venor Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Venor Pharma Limited's manufacturing facility in Dehradun, Uttarakhand, has been inspected and approved by the U.S. Food and Drug Administration (FDA). This approval signifies the facility's compliance with FDA standards, facilitating the export of pharmaceutical products to the United States. The company's adherence to FDA regulations underscores its commitment to quality and safety in its manufacturing processes.

2WHO & EU GMP

Venor Pharma Limited's manufacturing facility holds the World Health Organization's Good Manufacturing Practice (WHO-GMP) certification, ensuring compliance with international manufacturing standards. Additionally, the facility aligns with European Union Good Manufacturing Practice (EU GMP) standards, further demonstrating its commitment to quality and regulatory compliance. These certifications enable the company to export its pharmaceutical products to various international markets, including those in the European Union.

3CDSCO & Indian Regulatory

Venor Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Venor Pharma Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products. The company's focus on controlled drug items, including narcotics and psychotropic substances, positions it uniquely in the market. Its adherence to international manufacturing standards and possession of multiple regulatory approvals provide a competitive edge, enabling access to various global markets. However, the company faces competition from both domestic and international manufacturers in the controlled substances segment.

2Key Differentiators

Venor Pharma Limited's key differentiators include its specialization in controlled drug items, adherence to international manufacturing standards, and possession of multiple regulatory approvals. The company's manufacturing facility's certifications, such as WHO-GMP and EU GMP, underscore its commitment to quality and compliance. These factors enable Venor Pharma Limited to effectively serve diverse international markets, including Europe, the Middle East, South America, and South Asia.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Venor Pharma Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Venor Pharma Limited has demonstrated a consistent track record in the pharmaceutical industry, with a total export value of $8.6 million USD and 497 shipments across nine products in four therapeutic categories. The company's portfolio concentration, with the top five products accounting for 94.7% of exports, indicates a focused approach to its product offerings. The absence of publicly available records indicating regulatory issues further underscores the company's reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Venor Pharma Limited as a supplier:

FDA Approval: Confirm the facility's registration and compliance with FDA standards.
WHO-GMP Certification: Ensure the manufacturing facility holds WHO-GMP certification.
EU GMP Certification: Verify the facility's compliance with EU GMP standards.

Frequently Asked Questions — Venor Pharma Limited

How many pharmaceutical products does Venor Pharma Limited export from India?

Venor Pharma Limited exports 9 pharmaceutical products across 4 therapeutic categories. The top exports are Morphine ($4.4M), Diazepam ($1.4M), Fentanyl ($1.2M), Codeine ($740.8K), Ephedrine ($395.9K). Total export value is $8.6M.

What is Venor Pharma Limited's total pharmaceutical export value?

Venor Pharma Limited's total pharmaceutical export value is $8.6M, based on 497 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Venor Pharma Limited the #1 Indian exporter?

Venor Pharma Limited is the #1 Indian exporter in 1 products: Diazepam (18.4% market share).

What therapeutic categories does Venor Pharma Limited cover?

Venor Pharma Limited exports across 4 therapeutic categories. The largest are Analgesics & Antipyretics (74.0%, 3 products), CNS & Psychiatric (18.5%, 3 products), Respiratory & OTC (4.6%, 1 products).

Get Full Venor Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.